RT Journal Article
SR Electronic
T1 Pediatric critical COVID-19 and mortality in a multinational cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.20.21262122
DO 10.1101/2021.08.20.21262122
A1 Gonzalez-Dambrauskas, Sebastian
A1 Vasquez-Hoyos, Pablo
A1 Camporesi, Anna
A1 Cantillano, Edwin Mauricio
A1 Dallefeld, Samantha
A1 Dominguez-Rojas, Jesus
A1 Francoeur, Conall
A1 Gurbanov, Anar
A1 Vega, Liliana Mazzillo
A1 Shein, Steven
A1 Yock-Corrales, Adriana
A1 Karsies, Todd
A1 on behalf of Critical Coronavirus and Kids Epidemiological (CAKE) Study Investigators
YR 2021
UL http://medrxiv.org/content/early/2021/08/23/2021.08.20.21262122.abstract
AB Objectives To understand the international epidemiology of critical pediatric COVID-19 and compare presentation, treatments, and outcomes of younger (<2 years) and older (>2 years) children.Design Prospective, observational study from April 1 to December 31, 2020Setting International multicenter study from 55 sites from North America, Latin America, and Europe.Participants Patients <19 years old hospitalized with critical COVID-19Interventions noneMain outcomes measured Clinical course, treatments, and outcomes were compared between younger and older children. Multivariable logistic regression was used to calculate adjusted odds ratios (aOR) for hospital mortality.Results 557 subjects (median age, 8 years; 24% <2 years) were enrolled from 55 sites (63% Latin American). Half had comorbidities. Younger children had more respiratory findings (56% vs 44%), viral pneumonia (45% vs 29%), and treatment with invasive ventilation (50% vs 37). Gastrointestinal (28% vs 69%) or mucocutaneous (16% vs 44%) findings, vasopressor requirement (44% vs 60%), and MIS-C (15% vs 40%) were less common in younger children. Hospital mortality was 10% overall but 15% in younger children (odds ratio 1.89 [95%CI 1.05-3.39]). When adjusted for age, sex, region, and illness severity, mortality-associated factors included cardiac (aOR 2.6; 95%CI 1.07-6.31) or pulmonary comorbidities (aOR 4.4; 95%CI 1.68-11.5), admission hypoxemia (aOR 2.33; 95%CI 1.24-4.37), and lower respiratory symptoms (aOR 2.83; 95%CI 1.49-5.39). Gastrointestinal (aOR 0.49; 95%CI 0.26-0.92) or mucocutaneous symptoms (aOR 0.31; 95%CI 0.15-0.64), treatment with intravenous immune globulin (aOR 0.33; 95%CI 0.17-0.65), and MIS-C (aOR 0.26; 95%CI 0.11-0.64) were associated with lower mortality.Conclusions We identified age-related differences in presentation and mortality for critical pediatric COVID-19 that should prompt more attention to improving management in younger children, especially in developing countries.Table of Contents Summary This is a multinational study describing critical pediatric COVID-19 clinical spectrum and related mortality in high and low-middle income countries during 2020.What’s known on this subject Pediatric critical illness due to COVID-19 is uncommon and have lower mortality compared to adults when hospitalized. While larger cohorts are from high-income countries (HICs), studies including data from low-middle-income countries (LMICs) remain scarce.What this study adds In our multinational cohort of critical pediatric COVID-19, we identified higher mortality than previously reported and age-related disease patterns. Children <2 years old had more respiratory disease and higher mortality, and older children had more non-pulmonary disease and better outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the lead site, Nationwide Children's Institutional Review Board, and each institutional review board at each participating site with a waiver of the need for informed consent (supplemental data, collaborators).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.COVID-19coronavirus disease 2019ICUintensive care unitPICUpediatric intensive care unitHIChigh-income countryLMIClow-middle-income countryMIS-Cmultisystem inflammatory syndrome in childrenHFNChigh flow nasal cannulaNIVnoninvasive ventilationIMVinvasive mechanical ventilationCRRTcontinuous renal replacement therapyARDSacute respiratory distress syndromeCDCCenters for Disease Control and PreventionLOSlength of stayPRISM IIIPediatric Risk of Mortality IIIPELOD-2Pediatric Logistic Organ Dysfunction 2IQRinterquartile rangeCIconfidence intervalBNPbrain natriuretic peptideIVIGintravenous immune globulinECMOextracorporeal membrane oxygenationHCQhydroxychloroquineORodds ratioaORadjusted odds ratio